The recent recommendations from a Food and Drug Administration (FDA) advisory committee about safety concerns with contraceptives may make women more leery when deciding which birth control is best for them. But even for women who are currently on birth control, understanding the risks is vital.
The benefits of using birth control pills outweigh the risks, according to a Style Bistro story, which supports the use of oral contraceptives for the treatment of acne. There are three birth control pills that are FDA-approved for such use – Ortho Tri-Cyclen, Estrostep, and Yaz. The latter of these is one of the nation’s most prescribed birth control pills. It is also under a new safety review by the FDA based on data that links use of the pills to serious and life threatening health risks.
Health insurance plans will soon be required to cover birth control at no cost to women, thanks to new requirements ordered by the Obama administration. The new rules are part of a broad spectrum of women’s preventative coverage and include breast pumps for nursing mothers, an annual “well woman” physical, counseling on how to avoid sexually transmitted diseases, and other services with no co-pay. Insurance companies can recoup any losses by increasing their premiums. The new benefits won’t go into effect for at least another year.
Bayer AG has its eyes set on the Latin American country Brazil to win back profits lost from lawsuits and bad press surrounding its blockbuster birth control pill Yaz. The German pharmaceutical company announced this week that it expects to post double-digit annual growth in Brazil through the next four years, from 15 billion in 2008 to a whopping $27 billion by 2015.
The Food and Drug Administration (FDA) is reminding drug companies that they are required to disclose side effects or risks about their medications in advertising, even banner ads and Facebook “share” buttons. The agency recently required Novartis Pharmaceuticals to take down a Facebook Share button used to promote a cancer-fighting drug, saying it was “incomplete and misleading” and violated advertising disclosure requirements. Novartis removed the widget but says it will continue to discuss the parameters of web advertising and social media marketing with the FDA in order to fully understand the agency’s concerns.
Bayer has launched a new marketing campaign aimed at encouraging women to understand the risks and benefits of their birth control method, including those offered by Bayer. The drug company boasts the most popular birth control pills on the market – Yaz and Yasmin – which have brought in more than $1.5 billion since 2009. The pills are also bringing something new to Bayer – more than 1,000 lawsuits from women who claim they were not adequately warned by the company of the serious health risks associated with Yaz and Yasmin.
